London, 18 July 2006 - Lawyers from the London office of Morrison & Foerster advised a group of investors including Avlar BioVentures, Bio*One Capital, Merlin Biosciences and Lloyds TSB Development Capital on a Series D private equity funding for Paradigm Therapeutics Limited ("Paradigm") totalling approximately £7 million.

Paradigm is a Cambridge-based drug discovery company.

The Morrison & Foerster team included Paul Claydon and James Halstead.